Overview: CD15 Immunohistochemistry TestIntroduction: The CD15 Immunohistochemistry Test detects CD15 protein to diagnose Hodgkin lymphoma, causing lymph node swelling or fever. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected Hodgkin lymphoma.
Other Names: CD15 IHC Assay, Hodgkin Lymphoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: CD15 testing began in the 1980s with lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects CD15 to diagnose Hodgkin lymphoma, guides treatment, and evaluates patients with lymph node swelling or fever.
Test Parameters: 1. CD15 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, fever, or night sweats.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fever, night sweats, or family history of lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, lymphoma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect CD15 in lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for Hodgkin lymphoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive CD15 staining suggests Hodgkin lymphoma, guiding chemotherapy or radiation. Negative staining may require further lymphoma marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD30 IHC, EBV testing, or PET-CT to confirm Hodgkin lymphoma diagnosis.
Test Limitations: Not specific to Hodgkin lymphoma; other conditions may express CD15. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
